Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements

Fineline Cube Jul 13, 2026
Company Deals

Teva Secures Global Rights to Polpharma Biologics’ Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio

Fineline Cube Jul 13, 2026
Company Deals

Drug Farm Closes First Tranche of $55 Million Series D Financing to Advance First-in-Class Pipeline Across Multiple Therapeutic Areas

Fineline Cube Jul 13, 2026
Company Deals

Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development

Fineline Cube Jul 13, 2026
Company Deals

Triastek Secures Strategic Financing to Advance 3D-Printed Oral Peptide Pipeline and Build Shanghai International R&D Center

Fineline Cube Jul 13, 2026
Policy / Regulatory

China’s National Health Commission Launches Comprehensive Continuous Medication Management Framework to Enhance Patient Safety and Healthcare Quality

Fineline Cube Jul 13, 2026
Company Drug

EMA CHMP Recommends Revocation of TAVNEOS Marketing Authorization Following Data Integrity Concerns in ADVOCATE Trial

Fineline Cube Jul 13, 2026
Company Drug

Abbisko Therapeutics Secures FDA IND Clearance for Pan-KRAS Inhibitor ABSK211, Targeting Broad Spectrum of KRAS Alterations in Solid Tumors

Fineline Cube Jul 13, 2026
Company Deals

Shenzhen TargetRx Raises $50M in Series C Financing for Global Clinical Trials

Fineline Cube Jan 23, 2025

China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, has announced the completion of...

Company Drug

Haisco’s HSK44459 Approved for Clinical Trials in Behcet’s Disease

Fineline Cube Jan 23, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving clinical trial approval from...

Company Deals

Fosun’s Plan to Take Henlius Private Fails After Shareholder Vote

Fineline Cube Jan 23, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its plan...

Company Drug

Belief BioMed’s BBM-D101 Receives FDA Approval for DMD Clinical Trial

Fineline Cube Jan 23, 2025

China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced receiving clinical trial approval from...

Company Medical Device

Roche’s cobas liat STI Assay Panels Gain FDA Approval and CLIA Waiver

Fineline Cube Jan 23, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced receiving approval from the US...

Company Drug

United Laboratories’ UBT251 Approved for Phase II Trials in Chronic Kidney Disease

Fineline Cube Jan 23, 2025

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced receiving approval from the...

Company Drug

Sanofi’s Sarclisa Approved in EU for Newly Diagnosed Multiple Myeloma

Fineline Cube Jan 23, 2025

France-based Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving marketing approval in the European Union...

Company Deals

Eli Lilly and Merck Launch Consortium for Innovative Drug Manufacturing

Fineline Cube Jan 23, 2025

US-based Eli Lilly and Company (NYSE: LLY) and Merck & Co. Inc. (NYSE: MRK) have...

Company Deals

Akeso Biopharma Receives Development Payment for PD-L1 Monoclonal Antibody

Fineline Cube Jan 22, 2025

China-based Akeso Biopharma (HKG: 9926) has announced receiving a drug collaboration development payment from compatriot...

Company Deals

Shanghai Bao Pharmaceuticals Launches IPO to Advance Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2025

China-based Shanghai Bao Pharmaceuticals Co., Ltd., a high-end biopharmaceuticals developer, has announced its initial public...

Company Deals

Degron Therapeutics Secures $20M Series A+ for Molecular Glue Drug Development

Fineline Cube Jan 22, 2025

China-based Degron Therapeutics, a specialist in molecular glue-based drugs, has reportedly raised over USD 20...

Company Drug

FDA Lifts Clinical Hold on Sanofi’s Cialis Over-the-Counter Trial

Fineline Cube Jan 22, 2025

France-based Sanofi’s (NASDAQ: SNY, EPA: SAN) Consumer Healthcare unit Opella has announced that the US...

Company Drug

Johnson & Johnson’s Spravato Approved as Monotherapy for Major Depressive Disorder

Fineline Cube Jan 22, 2025

US-based Johnson & Johnson (J&J; NYSE: JNJ) has announced that its Spravato (esketamine) CIII nasal...

Company Drug

CD Biopharma Initiates Phase I Trial for CD-001 in Advanced Solid Tumors

Fineline Cube Jan 22, 2025

Suzhou-based tumor immunotherapy specialist CD Biopharma has announced the first subject dosing of a Phase...

Company Medical Device

Kehua Bioengineering Gains NMPA Approval for Gene Polymorphism Detection Kits

Fineline Cube Jan 22, 2025

China-based Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022) has announced receiving marketing approvals from the...

Company Drug

Humanwell’s HWH340 Receives Clinical Approval for Prostate Cancer Treatment

Fineline Cube Jan 22, 2025

Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that its Class 1 chemical drug...

Company Deals

Sichuan Biokin Re-submits IPO Application to Hong Kong Stock Exchange

Fineline Cube Jan 22, 2025

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has resubmitted its application...

Company Medical Device

Acotec’s Vericor-S2 Coronary Microcatheter Approved by NMPA

Fineline Cube Jan 22, 2025

Acotec Scientific Holdings Ltd (HKG: 6669) has announced that its Vericor-S2 coronary microcatheter has received...

Company Deals

Lepu Biopharma Licenses Potential Best-in-Class ADC MRG007 to ArriVent

Fineline Cube Jan 22, 2025

Lepu Biopharma Co., Ltd (HKG: 2157) has announced an exclusive licensing agreement with ArriVent BioPharma,...

Policy / Regulatory

Trump Signs Executive Order to Withdraw from WHO, Drawing Criticism

Fineline Cube Jan 21, 2025

President Donald Trump has signed an executive order indicating the withdrawal of the United States...

Posts pagination

1 … 250 251 252 … 694

Recent updates

  • Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements
  • Teva Secures Global Rights to Polpharma Biologics’ Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio
  • EMA CHMP Recommends Revocation of TAVNEOS Marketing Authorization Following Data Integrity Concerns in ADVOCATE Trial
  • China’s National Health Commission Launches Comprehensive Continuous Medication Management Framework to Enhance Patient Safety and Healthcare Quality
  • Drug Farm Closes First Tranche of $55 Million Series D Financing to Advance First-in-Class Pipeline Across Multiple Therapeutic Areas
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements

Company Deals

Teva Secures Global Rights to Polpharma Biologics’ Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio

Company Drug

EMA CHMP Recommends Revocation of TAVNEOS Marketing Authorization Following Data Integrity Concerns in ADVOCATE Trial

Policy / Regulatory

China’s National Health Commission Launches Comprehensive Continuous Medication Management Framework to Enhance Patient Safety and Healthcare Quality

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.